Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder: A Randomized Clinical Trial (September 2017) Doi: Lisdexamfetamine Dimesylate (Vyvanse), A Prodrug Stimulant for Attention-Deficit/Hyperactivity Disorder (May 2010) Doi: The Influence of Depressive Symptoms on Executive Functioning in Binge Eating Disorder: A Comparison of Patients and Non-Obese Healthy Controls (April 2019) Doi: Selective Serotonin Reuptake Inhibitors and Adverse Effects: A Narrative Review (August 05, 2021) Doi: SSRI Antidepressant Medications: Adverse Effects and Tolerability (February 01, 2001) Doi: Treatment of Obese Patients With Binge Eating Disorder Using Topiramate: A Review (July 07, 2009) Doi: Successful Treatment of Binge Eating Disorder With the GLP-1 Agonist Semaglutide: A Retrospective Cohort Study (August 08, 2023) Doi:

By signaling your brain that youre full and helping your body manage glucose, semaglutide works on two key fronts: reducing calorie intake and enhancing metabolic efficiency
Administered via weekly injections, it effectively aids in weight management by reducing hunger, enhancing insulin production, and slowing gastric emptying
Following BPD, the 24-hour mean circulating leptin concentration decreased from 51.94 9.21 to 15.04 4.80 ng/ml, while insulin levels dropped from 54.84 6.51 to 10.03 1.48 ng/ml
It changed my life
Alternative multi-agonists for obesity treatment GLP-1R/GcgR dual agonists have shown impressive metabolic benefits and inspired the search for what now represents a growing class of rationally designed multi-agonists with differentiated mechanisms of action for obesity therapy